Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

27.53 +0.29 (+1.06%)
Streaming Delayed Price Updated: 12:46 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 534,729
Open 27.11
Bid (Size) 27.53 (1)
Ask (Size) 27.55 (1)
Prev. Close 27.24
Today's Range 27.10 - 27.77
52wk Range 24.53 - 42.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 8 Analyst Ratings Have To Say About Genmab
Via Benzinga
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. 
Via Chartmill

Performance

YTD
-14.26%
-14.26%
1 Month
+6.71%
+6.71%
3 Month
-2.82%
-2.82%
6 Month
-4.14%
-4.14%
1 Year
-32.69%
-32.69%

More News

Read More
NASDAQ:GMAB, an undervalued stock with good fundamentals.
Via Chartmill
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
Via Benzinga
Exposures Product Safety
10 Analysts Assess Genmab: What You Need To Know
Via Benzinga
What 9 Analyst Ratings Have To Say About Genmab
Via Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
Via Chartmill
7 Stocks That Could Safely 10X by 2030
Via InvestorPlace
Decoding 9 Analyst Evaluations For Genmab
Via Benzinga
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
From Genmab A/S
Via Business Wire
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
From Genmab A/S
Via Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.